Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters

Language
Document Type
Year range
1.
American Journal of Transplantation ; 22(Supplement 3):406-407, 2022.
Article in English | EMBASE | ID: covidwho-2063395

ABSTRACT

Purpose: To date studies of children with a kidney transplant and COVID-19 are limited. The Improving Renal Outcomes Collaborative (IROC) is a learning health network in the US comprised of 36 pediatric kidney transplant programs that provides infrastructure to efficiently conduct multicenter studies. Method(s): We collected COVID-19 testing, indications, and outcomes data. Data were linked to patient demographic and clinical data in the IROC registry. We previously reported the results of this effort from April 6-September 3, 2020 (era 1). Here we report data from September 4, 2020 - February 28, 2021 (era 2). We describe the differences in testing frequency and positive testing over the two eras. Result(s): In era 1, 22 centers submitted testing data;in era 2, 21 centers submitted testing data. There were 281 tests in 281 patients analyzed in era 1 and 648 tests for 465 patients in era 2. From era 1 to era 2, the proportion of positive tests increased from 24/281 (8.54%) to 109/465 (23%). Testing frequency and results from eras 1 and 2 are displayed in Figure 1. 133 patients tested positive for COVID-19 over both eras, and there was no difference in the symptoms at the time of testing between the two eras. The most common symptoms for both eras were fever (35%), cough (33%), rhinorrhea (23%), vomiting (14%), and diarrhea (14%). Over both eras, 41/133 (31%) that tested positive for COVID-19 had no symptoms at the time of testing. There were no differences in outcomes between the two eras. 117 patients (88%) had no transplant complications. 1 (0.8%) patient had T cell-mediated rejection, 3 (2%) had antibody-mediated rejection, 1 (0.8%) had mixed T cell- and antibodymediated rejection, 10 (7.5%) had acute kidney injury, 1 (0.8%) experienced graft failure, and 1 patient (0.8%) died from their COVID-19 infection. Conclusion(s): In this cohort, there was overall more testing and more positive COVID-19 tests in era 2. The dates of era 2 correspond with children returning to school and the Winter surge in cases in the US. Despite the increased number and proportion of positive patients, the clinical outcomes are consistent with reported outcomes for their non-immunosuppressed peers. Follow-up studies will be required to evaluate whether the availability of vaccines for adolescents and the rise of the delta variant as the predominant strain affect clinical outcomes. (Table Presented).

2.
Pediatric Transplantation ; 26:2, 2022.
Article in English | Web of Science | ID: covidwho-1801739
3.
Journal of the American Society of Nephrology ; 31:277, 2020.
Article in English | EMBASE | ID: covidwho-984909

ABSTRACT

Background: The impact of COVID-19 disease on previously healthy children has been minimal, yet there is limited data on the impact of COVID-19 on children and adolescents with kidney transplants. Methods: We used the existing infrastructure of the Improving Renal Outcomes Collaborative (IROC) learning health system to develop and rapidly implement a webbased registry for collecting clinical and outcomes data about COVID-19 disease in pediatric transplant recipients. We distributed the registry to 32 U.S. pediatric kidney transplant centers and requested clinical and outcomes data from all recipients suspected of having COVID-19 disease. Here, we present an interim analysis of the first 6 weeks of registry data. Results: Between April 6 and May 27, 2020, 18 IROC centers entered data on 99 pediatric kidney transplant recipients who had PCR based testing for COVID-19. 54 patients were tested due to symptoms of COVID-19 (most commonly fever and cough), 7 asymptomatic patients had a known COVID exposure. 34 patients were tested per hospital policy (e.g. pre-anesthesia), and 4 did not have a reported testing indication. Overall, 10/99 (10%) tested positive for COVID-19, 6 of whom had any symptoms, 3 had a known exposure with a COVID+ individual, and 1 was diagosed by a pre-anesthesia screen. Thus far, the clinical course and outcomes are known in 8/10 COVID-19+ patients: 5 received outpatient supportive care alone, 2 were admitted to intensive care and 1 was admitted to a non-intensive care inpatient unit. Transplant outcomes were excellent in all COVID-19+ patients. There were no cases with respiratory failure, acute kidney injury, or allograft rejection/failure. There were no deaths due to COVID-19 disease. Conclusions: In this interim analysis of the IROC learning health system, pediatric kidney transplant recipients had a relatively low incidence of COVID-19 disease and excellent short-term outcomes.

SELECTION OF CITATIONS
SEARCH DETAIL